Close Menu

NEW YORK (GenomeWeb) – Roche said today that it has received the CE mark for its Navify Mutation Profiler clinical software, which it launched today.

The software provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer. Along with it, Roche launched Navify Therapy Matcher, an optional clinical decision support app that helps clinicians link clinically actionable mutations to therapy options.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
22
Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.